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sAnorexia nervosa (AN) is a complex and heritable eating disorder characterized by dangerously
low body weight. Neither candidate gene studies nor an initial genome wide association study
(GWAS) have yielded significant and replicated results. We performed a GWAS in 2,907 cases
with AN from 14 countries (15 sites) and 14,860 ancestrally matched controls as part of the
Genetic Consortium for AN (GCAN) and the Wellcome Trust Case Control Consortium 3
(WTCCC3). Individual association analyses were conducted in each stratum and meta-analyzed
across all 15 discovery datasets. Seventy-six (72 independent) SNPs were taken forward for in
silico (two datasets) or de novo (13 datasets) replication genotyping in 2,677 independent AN
cases and 8,629 European ancestry controls along with 458 AN cases and 421 controls from
Japan. The final global meta-analysis across discovery and replication datasets comprised 5,551
AN cases and 21,080 controls. AN subtype analyses (1,606 AN restricting; 1,445 AN binge-
purge) were performed. No findings reached genome-wide significance. Two intronic variants
were suggestively associated: rs9839776 (P=3.01×10−7) in SOX2OT and rs17030795
(P=5.84×10−6) in PPP3CA. Two additional signals were specific to Europeans: rs1523921
(P=5.76×10−6) between CUL3 and FAM124B and rs1886797 (P=8.05×10−6) near SPATA13.
Comparing discovery to replication results, 76% of the effects were in the same direction, an
observation highly unlikely to be due to chance (P= 4×10−6), strongly suggesting that true findings
exist but that our sample, the largest yet reported, was underpowered for their detection. The
accrual of large genotyped AN case-control samples should be an immediate priority for the field.
Keywords
anorexia nervosa; eating disorders; GWAS; genome-wide association study; body mass index;
metabolic
Introduction
Anorexia nervosa (AN) is a perplexing biologically-influenced psychiatric disorder
characterized by the maintenance of dangerously low body weight, fear of weight gain, and
seeming indifference to the seriousness of the illness.1 AN affects ~1% of the population.2, 3
Females are disproportionately afflicted, although males also develop the condition.4 The
most common age of onset is 15-19 years;5 however, the incidence appears to be increasing
in the pre-pubertal period6 and in older adults.7 AN is often comorbid with major depressive
disorder, anxiety disorders, and multiple somatic complications.8-12 Although most
individuals recover, ~25% develop a chronic and relapsing course.13 AN ranks among the
ten leading causes of disability among young women14 and has one of the highest mortality
rates of any psychiatric disorder.15-19 The evidence base for treatment for AN has been
described as “weak,”20, 21 and treatment and extended inpatient hospitalizations for weight
restoration are costly.22, 23 In sum, the public health impact of AN is considerable, and AN
carries substantial morbidity, mortality, and personal, familial, and societal costs.
As with most idiopathic psychiatric disorders, the inheritance of AN is complex. The core
features of AN [i.e., the ability and determination to maintain low body mass index (BMI)]
are remarkably homogeneous across time and cultures.24, 25 Genetic epidemiological studies
have documented the familiality of AN (relative risk 11.3 in first-degree relatives of AN
probands)26, 27 and the estimated twin-based heritability of AN ranges from 33 to 84%.28-32
Genome-wide linkage studies did not narrow the genomic search space in a compelling
manner.33-35 Findings from candidate gene studies of AN resemble those for most complex
biomedical diseases—initial intriguing findings diminished by the absence of rigorous
replication.36-38
Boraska et al. Page 5
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sGiven the centrality of weight dysregulation to AN, genes implicated in the regulation of
body weight might also be involved in the etiology of AN.39, 40 Therefore genetic variants
with a profound effect on BMI are worthy of consideration.38
Two genome-wide association studies (GWAS) of AN have been conducted. One study that
used DNA pooling and genotyping with a modest number of microsatellite markers with
follow-up genotyping detected evidence for association with rs2048332 on chromosome 1,
but this finding did not reach genome-wide significance.41 A GWAS of 1033 AN cases from
the USA, Canada, and Europe compared with 3733 pediatric controls yielded no genome-
wide significant findings.42 Recently, a sequencing and genotyping study of 152 candidate
genes in 1205 AN cases and 1948 controls suggested a novel association of a cholesterol
metabolism influencing EPHX2 gene with susceptibility to AN.43
In recognition of the need for large-scale sample collections to empower GWAS, we
established the Genetic Consortium for Anorexia Nervosa (GCAN) in 2007—a worldwide
collaboration combining existing DNA samples of AN patients into a single resource. As
part of the Wellcome Trust Case Control Consortium 3 (WTCCC3), we have conducted the
largest GWAS for AN to date.
Materials and Methods
Discovery dataset
We conducted a GWAS across 15 discovery datasets, comprising a total of 2,907 AN cases
and 14,860 ancestrally matched controls of European origin (Table 1). All AN cases were
female. Diagnostic determination was via semi-structured or structured interview or
population assessment strategy based on DSM diagnostic criteria. Cases met DSM-IV
criteria for lifetime AN (restricting or binge-purge subtype) or lifetime DSM-IV eating
disorders “not otherwise specified” (EDNOS) AN-subtype (i.e., exhibiting the core features
of AN). We did not require the presence of amenorrhea as this criterion does not increase
diagnostic specificity.44, 45 Given the frequency of diagnostic crossover, a lifetime history of
bulimia nervosa was allowed.46 Exclusion criteria included the diagnosis of medical or
psychiatric conditions that might have confounded the diagnosis of AN (e.g., psychotic
disorders, mental retardation, or a medical or neurological condition causing weight loss).
Controls were carefully selected to match for ancestry within each site and chosen primarily
from existing GWAS genotypes through collaboration and genotyping repository (dbGAP)
access. Each site obtained ethical approval from the local ethics committee, and all
participants provided written informed consent in accordance with the Declaration of
Helsinki.
Genotyping, imputation and quality control
AN cases from the 15 sites were genotyped using Illumina 660W-Quad arrays (Illumina,
Inc., San Diego, CA, USA) at the Wellcome Trust Sanger Institute. Funding was available
only for genotyping AN cases. Thus, control genotypes were selected from existing datasets
matched as closely as possible to the ancestry of cases and Illumina arrays as similar as
possible to the 660W array (Table S1). Quality control (QC) of directly typed variants was
performed within each of the 15 case-control datasets (Table S2, Supplementary
Information).
Phasing and imputation was performed separately for each of the 15 datasets using a
common set of single nucleotide polymorphisms (SNPs) passing QC (Table S2) using the
program Impute2 v2.1.2 (Supplementary Information).47 The imputation reference panel
was HapMap 3 release 2. We used all available HapMap3 populations for imputation as it
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swas shown that the increase in the reference panel decreases error.48, 49 Post-imputation
filters were applied to remove SNPs with INFO scores < 0.4 or with MAF < 0.05. We
observe high imputation accuracy (as captured by the INFO score) across a range of minor
allele frequencies (Figure S1). There was high concordance between directly genotyped
variants with imputed dosages of the same variants after masking (Figure S2).
Statistical analysis
Single-SNP association analyses were performed under an additive genetic model separately
within each of the 15 datasets (Supplementary Information). We tested for association across
the autosomes and the non-pseudoautosomal region of the X chromosome. Imputation and
association analysis of the non-pseudoautosomal region of the chromosome X data were
based on females (2,907 AN cases and 10,594 controls). Association analyses were
performed using SNPTEST v2.2.049 under an additive model and using a score test. To
guard against false positives due to population stratification, we carried out association
analysis within each dataset and then combined the results using meta-analysis (for the
French dataset, the first principal component was added as a covariate). Fixed-effects meta-
analyses were performed using GWAMA.50 All 15 discovery datasets were corrected for the
genomic control (GC) inflation factor (λGC) prior to performing meta-analysis (Table S2;
Supplementary Information).
Replication
We prioritized directly genotyped and imputed SNPs for replication based on statistical
significance (P < 10−4), robust QC metrics, and vicinity to plausible candidate genes. In
total 96 SNPs (95 autosomal and one on chromosome X) in 66 genomic regions showed
nominal evidence for association. We selected 72 independent, uncorrelated variants
representing each of the 66 associated genomic regions and added 4 proxies for the most
associated SNPs resulting in 76 SNPs for replication. Cluster plots of all prioritized SNPs
were examined using Evoker51 in cases and controls separately to minimize the possibility
of spurious association due to genotyping error. We included 27 ancestry-informative
markers (AIMs) for genotyping in the replication datasets, to guard against population
stratification (Supplementary Information).52
Our replication data included 15 datasets—two existing in silico datasets and 13 datasets for
de novo genotyping (Table 1). The in silico dataset from the USA came from an existing
GWAS of AN genotyped using the Illumina HumanHap610 platform (Illumina, San Diego,
CA, USA)53 and the other in silico dataset came from Estonian Genome Center
(www.biobank.ee) and was genotyped using the Illumina OmniExpress array. De novo
genotyped samples included newly collected AN cases and controls from members of the
GCAN and samples from the same sites as the discovery samples that had failed GWAS QC
(including saliva and whole genome amplified samples). De novo SNP genotyping was
carried out using the iPLEX Gold Assay (Sequenom, Inc., San Diego, CA, USA). SNPs with
poor Sequenom design metrics were replaced with high-LD proxies. Sample and SNP QC
were performed within each replication dataset. QC included checking for sex
inconsistencies and exclusions based on sample call rate <80%, SNP call rate <90% and
exact Hardy-Weinberg Equilibrium (HWE) p<0.0001. In total, replication genotypes (in
silico and de novo) of 76 prioritized SNPs and 27 AIMs were available from 2,677 AN cases
and 8,629 controls of European ethnicity and 458 AN cases and 421 controls from Japan.
Association analyses of prioritized SNPs were performed under an additive genetic model
within each replication dataset with and without adjustment for AIMs. AIMs that showed
nominally significant p-values for allele frequency differences between de novo typed cases
and controls were used for conditional analysis (Table S3). As there were no qualitative
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sdifferences between these results, the main text reports the unadjusted results. The USA
replication dataset contained individuals who were related to individuals from the USA
discovery dataset. As such, those samples were excluded from the discovery dataset and
combined with replication USA samples to correctly account for relatedness between
samples for the final global meta-analysis and sign test. Software packages GenABEL54 and
GEMMA55 were used for replication analysis of the USA dataset. Fixed-effects meta-
analysis across the replication datasets was performed using GWAMA50 (with and without
adjustment for AIMs and in samples of European ancestry only, i.e., excluding Japan, also
with and without adjustment for AIMs). We also performed meta-analyses across the
discovery and replication datasets, comprising a total of 5,551 AN cases and 21,080 controls
(USA discovery samples were included only once as part of the replication phase). We
calculated the power of the final global meta-analysis using QUANTO.56
Seventy-two independent SNPs were used to compare the direction of effects between the
discovery and replication meta-analyses using R.57 For this analysis, the USA samples were
used only once as part of the replication meta-analysis.
Additional analyses
We performed three additional analyses: 1) genome-wide complex trait analysis (GCTA),
designed to estimate the proportion of phenotypic variance explained by genome-wide SNPs
for complex traits,58 a network analysis, and a gene-based association test (Supplementary
Information).
AN subtype analyses
Two subtype (Supplementary Information) association analyses were performed for the 76
prioritized SNPs across the discovery and replication datasets (Table 1). In total, the AN
restricting subtype global meta-analysis included 1,606 cases and the AN binge-purge
subtype analysis included 1,445 cases. Both analyses used the same set of 16,303 controls
(Supplementary Information).
Related traits
Using the discovery meta-analysis, we investigated evidence for association using SNP
results from published studies: 9 SNPs with nominal evidence of association with AN;42 14
SNPs suggestively associated with eating disorder-related symptoms, behaviors, or
personality traits;59, 60 89 SNPs with genome-wide significance in studies of BMI or
obesity;61, 62 and 15 SNPs related to morbid obesity.61 We also investigated evidence for
association across the 72 replication SNPs using published GWAS results from the
Psychiatric Genomics Consortium (https://pgc.unc.edu) for attention-deficit/hyperactivity
disorder (ADHD), schizophrenia, bipolar disorder, and major depressive disorder.63-66
Expression studies
We prioritized the top 20 SNPs in terms of statistical significance and quantified the
expression of the two nearest genes per SNP (Table S4) in 12 inbred strains of mice. We
obtained publicly available RNAseq data from whole brain tissue samples and used standard
software to map and count the sequence reads (Supplementary Information).
Results
Main association results
Of 1,185,559 imputed SNPs that passed QC, 287 showed evidence for association in the
discovery stage with P < 10−4. These variants represented 66 independent signals and had
Boraska et al. Page 8
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sfrequencies and effect sizes commensurate with observations in other common complex
diseases. One variant, not surrounded by other SNPs achieving low p-values and for which
genotypes were only available in two of the 15 initial study groups, surpassed genome-wide
significance (rs4957798, P=1.67×10−12) but was not subsequently replicated in the global
meta-analysis across discovery and replication samples. The overall λGC was 1.03 (Figures
S3 and S4). Seventy-six SNPs (of which 72 were independent) were prioritized for follow-
up through in silico and de novo replication (Table S5). Nine SNPs showed association with
P < 0.05 (minimum p-value was 0.003) in the replication dataset meta-analysis (binomial
P=0.0135) (Table S5). Based on 72 independent SNPs taken forward, we would expect
0.05×72=3.6 SNPs to reach P=0.05 by chance. The 0.0135 P value reflects this enrichment
in signal. No signals surpassed genome-wide significance (P=5×10−8) in the final global
meta-analysis across all discovery and replication samples (Table S5) or in the AN subtype
analyses (Tables S6-S7).
Of critical importance, we observed significant evidence of SNP effect sizes in the
replication data in the same direction as the discovery set (55/72 signals, sign test binomial
P=4×10−6). This enrichment was also observed for the AN restricting (58/72, P=8×10−8)
and binge-purge (56/72, P=1×10−6) subtype analyses. These results strongly indicate that the
prioritized set of variants is likely to contain true positive signals for AN but that the current
sample size is insufficient to detect these effects.
Our analysis revealed two notable variants: rs9839776 (P=3.01×10−7) in SOX2OT (SOX2
overlapping transcript) and rs17030795 (P=5.84×10−6) in PPP3CA (protein phosphatase 3,
catalytic subunit, alpha isozyme) (Table 2). Two additional signals emerged from the
analysis focused on European replication samples only: rs1523921 (P=5.76×10−6) located
between CUL3 (cullin 3) and FAM124B (family with sequence similarity 124B) and
rs1886797 (P=8.05×10−6) located 18kb from SPATA13 (spermatogenesis associated 13)
(Table S5). Four signals were in neurodevelopmental genes regulating synapse and neuronal
network formation (SYN2, NCAM2, CNTNAP2 and CTNNA2; Table 2).
AN subtype analyses
In the AN restricting subtype analyses, the two most significant signals were rs1523921 (as
in the main analysis, P=8.39×10−5) and rs10777211 (P=8.95×10−5) located 333kb from
ATP2B1 (ATPase, calcium transporting, plasma membrane 1), both detected in the
European-only analysis (Table S6). The most significant result for AN binge-purge analysis
was rs9839776 (as in the main analysis, P=3.97×10−4) in SOX2OT, also in Europeans only
(Table S7). Overall, signals from the main AN case-control analysis display similar levels of
association across both AN subtypes (Table S8).
Additional analyses
GCTA is technically challenging when synthesizing data across multiple strata with small
individual sample sizes. When we applied it to our data we saw great variability in the
estimates of variance and did not judge the results reliable. Results of the gene-based
association test and network analysis are presented in their entirety in Supplemental
Information and Figure S5, both of which were unremarkable.
Related traits
Nine out of the 11 previously reported variants suggestively associated with AN42 were
found in our discovery meta-analysis, and six of these 9 SNPs had the same direction of
effect as originally reported (P=0.508) (Table S9). Twelve out of 14 variants previously
reported to be associated with eating disorder-related symptoms, behaviors, and personality
traits59, 60 were found in our discovery meta-analysis and 7 had the same direction of effect
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s(P=0.774) (Table S10), with one SNP (inside RUFY1) having P<0.05 (binomial P=0.459).
We did not find evidence for signal enrichment in the 60 independent SNPs found in the
Psychiatric Genomics Consortium data for ADHD, schizophrenia, bipolar disorder, or major
depressive disorder63-66 (Table S11).
When we compared 76 (53 independent) SNPs from the AN results with 89 established
BMI/obesity SNPs,61, 62 five SNPs (inside NEGR1, PTBP2, TMEM18, FTO and MC4R) had
P<0.05 (binomial P=0.1906). Twenty-six of these 53 SNPs had the same direction of effect
as originally reported (binomial P value=1) (Table S12). Thirteen of 15 SNPs associated
with extreme obesity were extracted from our dataset and 9 of these were independent. Four
of these 9 SNPs had the same direction of effect as originally reported (binomial P value=1)
(Table S13). Three SNPs (in TMEM18, FTO and MC4R) had P<0.05 (binomial P
value=0.0084), indicating modest enrichment of nominally associated SNPs from extreme
obesity in our discovery dataset.
Expression studies
We analyzed RNAseq data for whole-brain tissue obtained from 12 different mouse strains
(Figure 1). We performed this analysis for 32 mouse orthologues of the 34 human genes
identified (Table S4). All 32 genes were expressed in the brain, above an average of 2
FPKM (Fragments Per Kilobase of exon per Million fragments mapped). Specifically, we
find extremely high expression levels for Ppp3ca (FPKM value 36.40). Further, we find
high expression for Sox2ot, with an FPKM value of 8.02, and similar expression values for
Cul3 (10.01) and Ctnna2 (10.79).
Discussion
Given that the evidence base for the treatment of AN remains weak and that no effective
medications for its treatment exist,20, 67 advances in our understanding of the underlying
biology of the disorder are essential in order to develop novel therapeutics and to reduce the
loss of life and diminution of quality of life associated with the disorder. The GCAN/
WTCCC3 investigation represents an unprecedented international genetic collaboration in
the study of AN, which sets the foundation for further genetic studies.
Our final global meta-analysis had 80% power to detect SNPs with allele frequency of 0.35
and genotypic relative risk of 1.15 (α=5×10−8, additive model).68 The AN subtype meta-
analysis had 80% power to detect SNPs with allele frequency of 0.35 and genotypic relative
risk 1.27 for the AN restricting subtype and 1.28 for the AN binge-purge subtype. Given
these limitations in power, our strongest indicator that larger sample sizes could detect
genetic variants associated with AN was revealed in the sign tests. The strong and
significant evidence for SNP effect sizes in the same direction between discovery and
replication sets (P=4×10−6) clearly suggests that larger sample sizes could successfully
identify variants associated with AN and with the AN subtypes potentially enabling
differentiation on a genetic level between restricting and binge/purge subtypes.
Several genetic variants were suggestively associated with AN (P<10−5) (Table 2). Two
variants, rs9839776 in SOX2OT and rs17030795 in PPP3CA, were identified through
analysis of all discovery and replication datasets. Two additional variants with P<10−5,
rs1523921 located between CUL3 and FAM124B and rs1886797 located near SPATA13,
were identified through analysis of individuals of European descent only (Table S5),
suggesting either heterogeneity in the effects of these SNPs by ancestry or low power. The
genes displayed in Table 2 are discussed in greater detail in the Supplementary Information;
however, we highlight that four of these variants are neurodevelopmental genes that regulate
synapse and neuronal network formation (SYN2, NCAM2, CNTNAP2 and CTNNA2) and two
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shave been associated with Alzheimer’s disease (SOX2OT and PPP3CA). Additionally, one
of our prioritized SNPs (rs6558000) (Table S5) is located in close vicinity (9kb upstream) of
the EPHX2 gene that was recently identified as a susceptibility locus to AN through
candidate gene sequencing study of early-onset severe AN cases and controls.43
Our expression studies further extend the GWAS findings. It is reasonable, although perhaps
not essential, to expect that genes implicated in AN be expressed in the brain. Supporting
this assumption, 32 mouse orthologues of 34 human genes identified as being of interest
were expressed at least at a low level in mouse brain. Moreover, genes corresponding to the
more strongly associated genetic variants tended to be more highly expressed. For example,
high FPKM values for Ppp3ca, Cul3, and Sox2ot underscore that these genes may play a
neuropsychiatric role.
AN subtype analyses were included to determine whether differences might exist between
the classic restricting subtype of AN and the subtype marked by dysregulation characterized
by binge eating and/or purging behavior. These analyses had lower power due to the smaller
sample sizes. Only two SNPs, rs1523921 (also found to be suggestively associated in the
main case-control analysis) and rs10777211 located 333kb upstream of ATP2B1, showed
association at the 10−5 significance level (Table S6). Similarly, subsequent analyses
pertaining to associated phenotypes (weight regulation: BMI/obesity loci,40, 61, 69, 70 and
loci for extreme obesity;61, 71, 72 psychiatric comorbidities: ADHD, schizophrenia, bipolar
disorder, and major depressive disorder) or previous equivocal association findings for AN
or eating disorders (AN variants,42 eating disorder related symptoms, behaviors, and
personality traits variants59, 60) did not reveal significant findings. More adequately powered
analyses that could allow us to detect variants that can distinguish between these two
subtypes could be clinically meaningful in predicting clinical course and outcome and
eventually in designing targeted therapeutics.
Our understanding of the fundamental genetic architectures of complex medical diseases and
psychiatric disorders has expanded rapidly.73 It has also become manifestly clear that
genomic searches for common variation via GWAS can successfully uncover biological
pathways of etiological relevance. The major limitation to discovery is sample size.74 A
recent GWAS for schizophrenia reported the identification of 22 genome-wide significant
loci for schizophrenia (21,000 cases and 38,000 controls), and the results yielded multiple
themes of clear biological and translational significance (e.g., calcium biology and miR-137
regulation).75 Moreover, given that cases and controls were derived from multiple sources
and genotyped on multiple platforms, imputation was essential. Although effective, the
preferred approach will always be to have samples genotyped on the same platform to
maximize comparability and the capacity to identify genomic associations.
Although the underlying biology of AN remains incompletely understood, the relative
homogeneity of the phenotype, replicated heritability estimates, and encouraging results of
the sign tests presented herein strongly encourage continuing this path of discovery.
Phenotypic refinement and the identification of biomarkers of illness (independent of
biomarkers of starvation) could assist with identification of risk loci. We believe that the
surest and fastest path to fundamental etiological knowledge about the biological basis of
AN is via GWAS in larger samples.74 This path is notably safe given that it relies on off-the-
shelf technology whose utility has been proven in empirical results for multiple biomedical
and psychiatric disorders. This approach is cost-effective due to recent sharp decreases in
genotyping pricing. Therefore, we believe that accrual of large genotyped AN case-control
samples should be an immediate priority for the field.
Boraska et al. Page 11
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sSupplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Wellcome Trust Sanger Institute The WTCCC3
This work was funded by a grant from the WTCCC3 WT088827/Z/09 entitled “A genomewide association study of
anorexia nervosa.”
Data Analysis Group: Carl A. Anderson1, Jeffrey C. Barrett1, James A.B. Floyd1, Christopher S. Franklin1,
Ralph McGinnis1, Nicole Soranzo1, Eleftheria Zeggini1.
UK Blood Services Controls: Jennifer Sambrook2, Jonathan Stephens2, Willem H. Ouwehand2.
1958 Birth Cohort Controls: Wendy L. McArdle3, Susan M. Ring3, David P. Strachan4.
Management Committee: Graeme Alexander5, Cynthia M. Bulik6, David A. Collier7, Peter J. Conlon8, Anna
Dominiczak9, Audrey Duncanson10, Adrian Hill11, Cordelia Langford1, Graham Lord12, Alexander P.
Maxwell13, Linda Morgan14, Leena Peltonen1, Richard N. Sandford15, Neil Sheerin12, Nicole Soranzo1, Fredrik
O. Vannberg11, Jeffrey C. Barrett1 (chair).
DNA, Genotyping, and Informatics Group: Hannah Blackburn1, Wei-Min Chen16, Sarah Edkins1, Mathew
Gillman1, Emma Gray1, Sarah E. Hunt1, Cordelia Langford1, Suna Onengut-Gumuscu16, Simon Potter1, Stephen
S Rich16, Douglas Simpkin1, Pamela Whittaker1.
1. The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
2. Division of Transfusion Medicine, Department of Haematology, University of Cambridge, NHSBT
Cambridge Centre, Long Road, Cambridge, CB2 0PT, UK
3. Department of Social Medicine, University of Bristol, Bristol BS8 2BN, UK
4. St. George’s University, Division of Community Health Sciences, London SW19 0RE, UK
5. Department of Hepatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2
0QQ, UK
6. Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
7. Institute of Psychiatry, King’s College London, London SE5 8AF
8. Department of Nephrology, Beaumont Hospital, Dublin, Ireland and Royal College of Surgeons Dublin,
Ireland
9. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK
10. Gibbs Building, 215 Euston Road, London NW1 2BE, UK
11. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX1 2JA, UK
12. MRC Centre for Transplantation, King’s College London, London SE1 9RT, UK
13. Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK
14. School of Molecular Medical Sciences, University of Nottingham, Nottingham NG7 2UH, UK
15. Academic Department of Medical Genetics, Cambridge University, Cambridge CB2 0QQ, UK
16. Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
Additional Wellcome Trust Acknowledgements
1. This work was supported by the WellcomeTrust (098051).
2. Eleftheria Zeggini is supported by the Wellcome Trust (098051).
3. Vesna Boraska is supported by Unity Through Knowledge Fund CONNECTIVITY PROGRAM
(“Gaining Experience” Grant 2A), The National Foundation for Science, Higher Education and
Technological Development of the Republic of Croatia (BRAIN GAIN-Postdoc fellowship) and the
Wellcome Trust (098051).
Boraska et al. Page 12
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s4. Christopher S Franklin is supported by the WTCCC3 project, which is supported by the Wellcome Trust
(WT090355/A/09/Z, WT090355/B/09/Z).
5. James A B Floyd is supported by the WTCCC3 project, which is supported by the Wellcome Trust
(WT090355/A/09/Z, WT090355/B/09/Z).
6. Lorraine Southam is supported by the Wellcome Trust (098051).
7. William N Rayner is supported by the Wellcome Trust (098051).
8. The Wellcome Trust Case Control Consortium 3 project is supported by the Wellcome Trust
(WT090355/A/09/Z, WT090355/B/09/Z).
9. We acknowledge use of data from the British 1958 Birth Cohort and the UK National Blood Service.
10. We obtained High Density SNP Association Analysis of Melanoma: Case-Control and Outcomes
Investigation dataset through dbGaP (dbGaP Study Accession: phs000187.v1.p1). Research support to
collect data and develop an application to support this project was provided by 3P50CA093459,
5P50CA097007, 5R01ES011740, and 5R01CA133996.
11. Laura Huckins acknowledges Wellcome Trust (098051) and the MRC (MR/J500355/1) and Ximena
Ibarra-Soria for advice on RNA-seq analysis.
Austria. Medical University of Vienna. The study was partly supported by the European Commission, Framework 5
research program, Integrated Project QLK1-CT-1999-00916 “Factors in Healthy Eating” given to the consortium
lead by Prof. J. Treasure and Prof. D. Collier, London. We thank Gerald Nobis, Dr. Maria Haidvogl, and Dr. Julia
Philipp for help with data collection and interview work.
Canada. Canadian Institutes of Health Research (CIHR). Zeynep Yilmaz was supported by a CIHR Doctoral
Research Award (Genetic Determinants of Low Body Weight in Anorexia Nervosa; funding reference:
GSD-111968). The Toronto authors would like to thank Sajid Shaikh, Maria Tampakeras, and Natalie Freeman for
DNA preparation and laboratory support.
Canada. The Ontario Mental Health Foundation (OMHF). The collection of the Toronto DNA samples was
supported by a grant from the OMHF, awarded to Allan S. Kaplan and Robert D. Levitan (Polymorphism in
Serotonin System Genes: Putative Role in Increased Eating Behaviour in Seasonal Affective Disorder and Bulimia
Nervosa).
Czech Republic. Charles University. The study was supported by grants IGA MZ ČR NS/10045-4 and IGA NT
14094/3 from the Czech Ministry of Education and Health and PRVOUK P24/LF1/3 and P26/LF1/4 Charles
University, Prague, and from the Marie Curie Research Training Network INTACT (MRTN-CT-2006-035988).
Finland. University of Helsinki. Academy of Finland Center of Excellence in Complex Disease Genetics (grant
numbers: 213506, 129680), ENGAGE – European Network for Genetic and Genomic Epidemiology, FP7-
HEALTH-F4-2007, grant agreement number 201413. Data collection in the Finnish Twin studies has been
supported by the National Institute of Alcohol Abuse and Alcoholism (grants AA-12502, AA-00145, and
AA-09203 to R J Rose and AA15416 and K02AA018755 to D M Dick), the Academy of Finland (grants 100499,
205585, 118555 and 141054, 265240, and 264146 to JK). AR and LK were supported by the Academy of Finland,
grants 259764 and 28327, respectively.
France. Institut National de la Santé et de la Recherche Médicale (INSERM), France. This French cohort was
recruited with grants from EC Framework V ‘Factors in Healthy Eating’ (a consortium coordinated by Janet
Treasure and David Collier, King’s College London), and from INRA/INSERM (4M406D), and the participation of
Audrey Versini’s work was supported by grants from ‘Région Ile-de-France’. Cases were ascertained from Sainte-
Anne Hospital (Paris) and Robert Debre Hospital (Paris).
Genetics of Anorexia Nervosa (GAN), National Institute of Mental Health. The data and collection of biomaterials
for the GAN study have been supported by the National Institutes of Health Grants (MH066122, MH066117,
MH066145, MH066296, MH066147, MH0662, MH066193, MH066287, MH066288, MH066146). The principal
investigators and co-investigators of this study were: University of Pittsburgh, Pittsburgh, PA: Walter Kaye, M.D.,
Bernie Devlin, Ph.D.; University of North Carolina at Chapel Hill, Chapel Hill, NC: Cynthia M Bulik, Ph.D.;
Roseneck Hospital for Behavioral Medicine, Prien and Department of Psychiatry, University of Munich, Germany:
Manfred M Fichter, M.D.; Kings College London, Institute of Psychiatry, London, UK: Janet Treasure, M.D.;
Toronto General Hospital, Toronto, Ontario, Canada: Allan Kaplan, M.D., D. Blake Woodside, M.D.; Laureate
Psychiatric Hospital, Tulsa, OK: Craig L. Johnson, Ph. D.; Weill Cornell Medical College, White Plains, NY:
Katherine Halmi, M.D.; Sheppard Pratt Health System, Towson, MD: Harry A. Brandt, M.D., Steve Crawford,
M.D.; Neuropsychiatric Research Institute, Fargo, ND; James E. Mitchell, M.D.; University of California at Los
Angeles, Los Angeles, CA: Michael Strober, Ph.D.; University of Pennsylvania, Philadelphia, PA: Wade Berrettini,
M.D., Ph.D.; and University of Birmingham, England: Ian Jones, M.D. We are indebted to the participating
Boraska et al. Page 13
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sfamilies for their contribution of time and effort in support of this study. The authors also wish to thank the Price
Foundation for sponsoring the earlier work of this collaboration and would like to thank the study managers and
clinical interviewers for their efforts in participant screening and clinical assessments.
Germany. University of Duisburg-Essen. Sample collection was funded by grants from the German Federal
Ministry of Education and Research (BMBF; EDNET 01GV0602, 01GV0624, 01GV0623 and 01GV0905,
NGFNplus: 01GS0820) and the IFORES program of the University of Duisburg-Essen. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Germany. Prof. Ehrlich’s work is supported by DFG grant EH 367/5-1 and the SFB 940.
GlaxoSmithKline (GSK), Leeds (Yorkshire Centre for Eating Disorders). The authors acknowledge the support of
the Medical Research Council and GlaxoSmithKline for providing financial support of this project. The support of
the Carnegie Trust in the form of a travel award is also acknowledged. We also acknowledge the help and support
of the Discovery and Pipeline Genetics, and Translational Medicine and Genetics departments at GSK for their
contributions to this study. In particular we would like to acknowledge Mike Stubbins, Julia Perry, Sarah Bujac,
David Campbell (at GSK currently or at the time when the study was performed), John Blundell (Leeds
University), and Evleen Mann (Yorkshire Centre for Eating Disorders), for their fundamental contribution to the
realization of this study.
Greece. Eating Disorders Unit, 1st Department of Psychiatry, Athens University, Medical School. Special thanks
goes to Associate Professor Varsou E, Head of Eating Disorders Unit, and Professor Papadimitriou G, Chairman
and Director of 1st Department of Psychiatry, Athens University, Medical School, for their advice and support.
Italy. Padua (BIOVEDA). BIOVEDA was funded thanks to a Grant of Veneto Region in 2009. Samples were
collected at Padua, Verona, Treviso, Vicenza and Portogruaro hospitals.
Netherlands. Department of Neuroscience and Pharmacology, The Rudolf Magnus Institute of Neuroscience,
University Medical Center, Utrecht and Rintveld, Center for Eating Disorders, Altrecht in Zeist. Marek K. Brandys
was supported by funding from the Marie Curie Research Training Network INTACT (Individually tailored stepped
care for women with eating disorders; reference number: MRTN-CT-2006-035988). Martien Kas was supported by
a ZonMW VIDI-grant (91786327) from The Netherlands Organization for Scientific Research (NWO).
Norway. The National Institute of Public Health Twin Panel (NIPHTP). The NIPHTP was supported in part by
grants from The Norwegian Research Council, The Norwegian Foundation for Health and Rehabilitation, The
Norwegian Council for Mental Health and The European Commission under the program ‘Quality of Life and
Management of the Living Resources’ of 5th Framework Program (no. QLG2-CT-2002-01254).
Poland. Poznan University of Medical Sciences (PUMS). PUMS study was sponsored by KBN scientific grant no.
PO5B 12823
Spain. Department of Psychiatry University Hospital of Bellvitge-IDIBELL, Barcelona. Financial support was
received from Fondo de Investigación Sanitaria -FIS (PI11/210) and AGAUR (2009SGR1554). CIBER
Fisiopatología de la Obesidad y Nutrición (CIBERobn) is an initiative of ISCIII.
Sweden. Karolinska Institutet, Stockholm. The Swedish Twin Registry is supported by the Swedish Department of
Higher Education. The STR was supported by grants from the Ministry for Higher Education, the Swedish
Research Council (M-2005-1112 and 2009-2298), GenomEUtwin (EU/QLRT-2001-01254; QLG2-
CT-2002-01254), NIH grant DK U01-066134, The Swedish Foundation for Strategic Research (SSF; ICA08-0047),
the Swedish Heart-Lung Foundation, the Royal Swedish Academy of Science, and ENGAGE (within the European
Union Seventh Framework Programme, HEALTH-F4-2007-201413).
United Kingdom. King’s College London. Financial support was received from the European Union (Framework-V
Multicentre Research Grant, QLK1-1999-916), a Multicentre EU Marie Curie Research Training Network grant,
INTACT (MRTN-CT-2006-035988) and a Marie-Curie Intra-European Fellowship (FP-7-People-2009-IEF, No.
254774). Dr. Oliver Davis is supported by a Sir Henry Wellcome Fellowship from the Wellcome Trust
(WT088984). Cathryn Lewis is partly supported by the National Institute for Health Research (NIHR) Biomedical
Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of
Psychiatry, King’s College London.
United States. McLean Hospital/Harvard Medical School, Cambridge, MA. The collection of DNA from
participants at the McLean Hospital/Harvard Medical School site was supported in part by an investigator-initiated
grant from Ortho-McNeil Janssen Scientific Affairs (principal investigator: Dr. Hudson).
United States. University of North Carolina. Sample collection was funded by a grant from the Foundation of Hope,
Raleigh, North Carolina. Sara Trace, PhD, Jin Szatkiewicz, PhD, and Jessica Baker, PhD were funded by T32
Boraska et al. Page 14
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sMH076694 (PI:Bulik). Sara Trace was funded by a 2012-2015 Hilda and Preston Davis Foundation Postdoctoral
Fellowship Program in Eating Disorders Research Award. Stephanie Zerwas, PhD was funded by a UNC BIRWCH
award K12HD001441. The Clinical and Translational Science Award (CTSA) program at UNC-Chapel Hill
provided additional assistance UL1TR000083.
United States. Vanderbilt University School of Medicine, Nashville TN, and the Kartini Clinic for Disordered
Eating, Portland, OR. Cases were ascertained from the Kartini Clinic, Portland Oregon. Sample collection and
processing was funded by a Bristol-Myers Squibb Freedom to Discover Unrestricted Metabolic Diseases Research
Grant to RDC.
Replication Samples
Children’s Hospital of Philadelphia/Price Foundation. We gratefully thank all the patients and their families who
were enrolled in this study, as well as all the control subjects who donated blood samples to Children’s Hospital of
Philadelphia (CHOP) for genetic research purposes. We thank the Price Foundation for their support of the
Collaborative Group effort that was responsible for recruitment of patients, collection of clinical information and
provision of the DNA samples used in this study. The authors also thank the Klarman Family Foundation for
supporting the study. We thank the technical staff at the Center for Applied Genomics at CHOP for producing the
genotypes used for analyses and the nursing, medical assistant and medical staff for their invaluable help with
sample recruitments. CTB and NJS are funded in part by the Scripps Translational Sciences Institute Clinical
Translational Science Award [Grant Number U54 RR0252204-01]. All genome-wide genotyping was funded by an
Institute Development Award to the Center for Applied Genomics from the CHOP. 2011 - 2014 Davis Foundation
Postdoctoral Fellowship Program in Eating Disorders Research Award, Yiran Guo, PhD; 2012 - 2015 Davis
Foundation Postdoctoral Fellowship Program in Eating Disorders Research Award, Dong Li, PhD.
Estonia. Estonian Genome Center of the University of Tartu (EGCUT). EGCUT received targeted financing from
Estonian Government SF0180142s08, Center of Excellence in Genomics (EXCEGEN) and University of Tartu
(SP1GVARENG). We acknowledge EGCUT technical personnel, especially Mr. V. Soo and S. Smit. Data analyzes
were carried out in part in the High Performance Computing Center of University of Tartu.
Japan. National Institute of Mental Health, National Center of Neurology and Psychiatry. The data and sample
collection have been supported by Grants-in-Aid for Scientific Research 20390201 and 23390201 to G. Komaki
from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. We are indebted to the members
of the Japanese Genetic Research Group For Eating Disorders for their contribution of time and effort in collecting
samples and clinical data.
The Price Foundation Collaborative Group. Harry Brandt, Steve Crawford, Scott Crow, Manfred M. Fichter,
Katherine A. Halmi, Craig Johnson, Allan S. Kaplan, Maria La Via, James Mitchell, Michael Strober, Alessandro
Rotondo, Janet Treasure, D. Blake Woodside, Cynthia M. Bulik, Pamela Keel, Kelly L. Klump, Lisa Lilenfeld,
Laura M. Thornton, Kathy Plotnicov, Andrew W. Bergen, Wade Berrettini, Walter Kaye, and Pierre Magistretti.
Acknowledgements for Controls
Austria. Controls in Vienna were collected with support to Harald Aschauer by Österreichische Nationalbank (ÖNB
Project Nr. 5777 and 13198), Austrian Science Fund (Pr. Nr. P7639), European Science Foundation (ESF
Programme MNMI) and European Commission (Biomed 1, J1182E25A).
Canada. NIH grant No. - U24 CA074783 to S. Gallinger. This work was made possible through collaboration and
cooperative agreements with the Colon Cancer Family Registry and PIs. The content of this manuscript does not
necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating institutions or
investigators in the Colon CFR, nor does mention of trade names, commercial products, or organizations imply
endorsement by the US Government or the Colon CFR.
Czech Republic. Support came from the European Regional Development Fund and the State Budget of the Czech
Republic (RECAMO, CZ.1.05/2.1.00/03.0101).
dbGAP DAC. Research support to collect data and develop an application to support this project was provided by
3P50CA093459, 5P50CA097007, 5R01ES011740, and 5R01CA133996.
Germany. We thank all probands from the community-based cohorts of PopGen, KORA, and the Heinz Nixdorf
Recall (HNR) study. This study was supported by the German Federal Ministry of Education and Research
(BMBF), within the context of the National Genome Research Network plus (NGFNplus), and the MooDS-Net
(grant 01GS08144 to S.C.). The KORA research platform was initiated and financed by the Helmholtz Center
Munich, German Research Center for Environmental Health, which is funded by the BMBF and by the State of
Bavaria. The Heinz Nixdorf Recall cohort was established with the support of the Heinz Nixdorf Foundation.
Boraska et al. Page 15
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sGreece. This research has been co-financed by the European Union (European Social Fund – ESF) and Greek
national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic
Reference Framework (NSRF) - Research Funding Program: Heracleitus II. Investing in knowledge society through
the European Social Fund.
Italy (North), Verona. The INCIPE study was co-sponsored by Fondazione Cassa di Risparmio di Verona, Azienda
Ospedaliera di Verona, and University of Verona. Samples were collected in Verona, Padua, Monselice and Dolo.
Co-principal investigators were Antonio Lupo and Giovanni Gambaro.
Netherlands. Genotyping of controls was funded by NIH/NIMH R01 MH078075, granted to Roel Ophoff.
Spain. Spanish Plan Nacional SAF2008-00357 (NOVADIS); the Generalitat de Catalunya AGAUR 2009
SGR-1502; the Instituto de Salud Carlos III (FIS/FEDER PI11/00733); and the European Commission 7th
Framework Program, Project N. 261123 (GEUVADIS), and Project N. 262055 (ESGI).
References
1. Klump KL, Bulik CM, Kaye WH, Treasure J, Tyson E. Academy for Eating Disorders position
paper: eating disorders are serious mental illnesses. Int J Eat Disord. 2009; 42:97–103. [PubMed:
18951455]
2. Hudson JI, Hiripi E, Pope HG Jr. Kessler RC. The prevalence and correlates of eating disorders in
the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 61:348–358. [PubMed:
16815322]
3. Hoek H, van Hoeken D. Review of the prevalence and incidence of eating disorders. Int J Eat
Disord. 2003; 34:383–396. [PubMed: 14566926]
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth
Edition. American Psychiatric Press; Washington, DC: 2000. Text Revision
5. Lucas AR, Beard CM, O’Fallon WM, Kurland LT. 50-year trends in the incidence of anorexia
nervosa in Rochester, Minn.: a population-based study. Am J Psychiatry. 1991; 148:917–922.
[PubMed: 2053633]
6. Nicholls DE, Lynn R, Viner RM. Childhood eating disorders: British National Surveillance Study.
Br J Psychiatry. 2011; 198:295–301. [PubMed: 21972279]
7. Bueno B, Krug I, Bulik C, Jiménez-Murcia S, Granero R, Thornton L, Penelo E, Menchón J,
Sánchez I, Tinahones F, Fernández-Aranda F. Late onset eating disorders in Spain: Clinical
characteristics and therapeutic implications. J Clin Psychol. in press.
8. Katzman D. Medical complications in adolescents with anorexia nervosa: a review of the literature.
Int J Eat Disord. 2005; 37:S52–59. [PubMed: 15852321]
9. Sharp C, Freeman C. The medical complications of anorexia nervosa. Br J Psychiatry. 1993;
162:452–462. [PubMed: 8481735]
10. Kaye W, Bulik C, Thornton L, Barbarich BS, Masters K, Group PFC. Comorbidity of anxiety
disorders with anorexia and bulimia nervosa. Am J Psychiatry. 2004; 161:2215–2221. [PubMed:
15569892]
11. Godart N, Flament M, Perdereau F, Jeammet P. Comorbidity between eating disorders and anxiety
disorders: A review. Int J Eat Disord. 2002; 32:253–270. [PubMed: 12210640]
12. Fernandez-Aranda F, Pinheiro AP, Tozzi F, Thornton LM, Fichter MM, Halmi KA, Kaplan AS,
Klump KL, Strober M, Woodside DB, Crow S, Mitchell J, Rotondo A, Keel P, Plotnicov KH,
Berrettini WH, Kaye WH, Crawford SF, Johnson C, Brandt H, La Via M, Bulik CM. Symptom
profile of major depressive disorder in women with eating disorders. Aust N Z J Psychiatry. 2007;
41:24–31. [PubMed: 17464678]
13. Berkman ND, Lohr KN, Bulik CM. Outcomes of eating disorders: a systematic review of the
literature. Int J Eat Disord. 2007; 40:293–309. [PubMed: 17370291]
14. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: measuring
the loss of health from diseases, injuries and risk factors. Med J Aust. 2000; 172:592–596.
[PubMed: 10914105]
15. Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry. 1995; 152:1073–1074. [PubMed:
7793446]
Boraska et al. Page 16
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s16. Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and
other eating disorders. A meta-analysis of 36 studies. Arch Gen Psychiatry. 2011; 68:724–731.
[PubMed: 21727255]
17. Birmingham C, Su J, Hlynsky J, Goldner E, Gao M. The mortality rate from anorexia nervosa. Int
J Eat Disord. 2005; 38:143–146. [PubMed: 16134111]
18. Millar HR, Wardell F, Vyvyan JP, Naji SA, Prescott GJ, Eagles JM. Anorexia nervosa mortality in
Northeast Scotland, 1965-1999. Am J Psychiatry. 2005; 162:753–757. [PubMed: 15800149]
19. Zipfel S, Lowe B, Reas DL, Deter HC, Herzog W. Long-term prognosis in anorexia nervosa:
lessons from a 21-year follow-up study. Lancet. 2000; 355:721–722. [PubMed: 10703806]
20. Bulik CM, Berkman ND, Brownley KA, Sedway JA, Lohr KN. Anorexia nervosa treatment: a
systematic review of randomized controlled trials. Int J Eat Disord. 2007; 40:310–320. [PubMed:
17370290]
21. [Accessed November 15, 2013] Eating disorders: Core interventions in the treatment and
management of anorexia nervosa, bulimia nervosa and related eating disorders. 2004. http://
www.nice.org.uk/page.aspx?o=101239
22. McKenzie JM, Joyce PR. Hospitalization for anorexia nervosa. Int J Eat Disord. 1992; 11:235–
241.
23. Krauth C, Buser K, Vogel H. How high are the costs of eating disorders - anorexia nervosa and
bulimia nervosa - for German society? Eur J Health Econ. 2002; 3:244–250. [PubMed: 15609150]
24. Striegel-Moore RH, Bulik CM. Risk factors for eating disorders. Am Psychol. 2007; 62:181, 198.
[PubMed: 17469897]
25. Kas M, Kaye W, Mathes W, Bulik C. Interspecies genetics of eating disorders traits. Am J Med
Genets Part B; Neuropsychiatr Genet. 2009; 150B:318–327.
26. Strober M, Freeman R, Lampert C, Diamond J, Kaye W. Controlled family study of anorexia
nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes.
Am J Psychiatry. 2000; 157:393–401. [PubMed: 10698815]
27. Lilenfeld L, Kaye W, Greeno C, Merikangas K, Plotnikov K, Pollice C, Rao R, Strober M, Bulik
C, Nagy L. A controlled family study of restricting anorexia and bulimia nervosa: comorbidity in
probands and disorders in first-degree relatives. Arch Gen Psychiatry. 1998; 55:603–610.
[PubMed: 9672050]
28. Bulik C, Sullivan P, Tozzi F, Furberg H, Lichtenstein P, Pedersen N. Prevalence, heritability and
prospective risk factors for anorexia nervosa. Arch Gen Psychiatry. 2006; 63:305–312. [PubMed:
16520436]
29. Klump KL, Miller KB, Keel PK, McGue M, Iacono WG. Genetic and environmental influences on
anorexia nervosa syndromes in a population-based twin sample. Psychol Med. 2001; 31:737–740.
[PubMed: 11352375]
30. Wade TD, Bulik CM, Neale M, Kendler KS. Anorexia nervosa and major depression: shared
genetic and environmental risk factors. Am J Psychiatry. 2000; 157:469–471. [PubMed:
10698830]
31. Kortegaard LS, Hoerder K, Joergensen J, Gillberg C, Kyvik KO. A preliminary population-based
twin study of self-reported eating disorder. Psychol Med. 2001; 31:361–365. [PubMed: 11232922]
32. Bulik CM, Thornton LM, Root TL, Pisetsky EM, Lichtenstein P, Pedersen NL. Understanding the
relation between anorexia nervosa and bulimia nervosa in a Swedish national twin sample. Biol
Psychiatry. 2010; 67:71–77. [PubMed: 19828139]
33. Grice DE, Halmi KA, Fichter MM, Strober M, Woodside DB, Treasure JT, Kaplan AS, Magistretti
PJ, Goldman D, Bulik CM, Kaye WH, Berrettini WH. Evidence for a susceptibility gene for
anorexia nervosa on chromosome 1. Am J Hum Genet. 2002; 70:787–792. [PubMed: 11799475]
34. Devlin B, Bacanu S, Klump K, Bulik C, Fichter M, Halmi K, Kaplan A, Strober M, Treasure J,
Woodside DB, Berrettini WH, Kaye WH. Linkage analysis of anorexia nervosa incorporating
behavioral covariates. Hum Mol Genet. 2002; 11:689–696. [PubMed: 11912184]
35. Bacanu S, Bulik C, Klump K, Fichter M, Halmi K, Keel P, Kaplan A, Mitchell J, Rotondo A,
Strober M, Treasure J, Woodside D, Bergen A, Berrettini W, Kaye W, Devlin B. Linkage analysis
of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits
or covariates. Am J Med Genet B Neuropsychiatr Genet. 2005; 139:61–68. [PubMed: 16152574]
Boraska et al. Page 17
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s36. Slof-Op ’t Landt M, van Furth E, Meulenbelt I, Slagboom P, Bartels M, Boomsma D, Bulik C.
Eating disorders: From twin studies to candidate genes and beyond. Twin Res Hum Genet. 2005;
16:467–482. [PubMed: 16212836]
37. Bulik CM, Slof-Op’t Landt MC, van Furth EF, Sullivan PF. The genetics of anorexia nervosa. Ann
Rev Nutr. 2007; 27:263–275. [PubMed: 17430085]
38. Hinney A, Scherag S, Hebebrand J. Genetic findings in anorexia and bulimia nervosa. Prog Mol
Biol Transl Sci. 2010; 94:241–270. [PubMed: 21036328]
39. Hebebrand J, Remschmidt H. Anorexia nervosa viewed as an extreme weight condition: genetic
implications. Hum Genet. 1995; 95:1–11. [PubMed: 7814009]
40. Muller TD, Greene BH, Bellodi L, Cavallini MC, Cellini E, Di Bella D, Ehrlich S, Erzegovesi S,
Estivill X, Fernandez-Aranda F, Fichter M, Fleischhaker C, Scherag S, Gratacos M, Grallert H,
Herpertz-Dahlmann B, Herzog W, Illig T, Lehmkuhl U, Nacmias B, Ribases M, Ricca V, Schafer
H, Scherag A, Sorbi S, Wichmann HE, Hebebrand J, Hinney A. Fat mass and obesity-associated
gene (FTO) in eating disorders: evidence for association of the rs9939609 obesity risk allele with
bulimia nervosa and anorexia nervosa. Obes Facts. 2012; 5:408–419. [PubMed: 22797368]
41. Nakabayashi K, Komaki G, Tajima A, Ando T, Ishikawa M, Nomoto J, Hata K, Oka A, Inoko H,
Sasazuki T, Shirasawa S. Identification of novel candidate loci for anorexia nervosa at 1q41 and
11q22 in Japanese by a genome-wide association analysis with microsatellite markers. J Hum
Genet. 2009; 54:531–537. [PubMed: 19680270]
42. Wang K, Zhang H, Bloss CS, Duvvuri V, Kaye W, Schork NJ, Berrettini W, Hakonarson H. A
genome-wide association study on common SNPs and rare CNVs in anorexia nervosa. Mol
Psychiatry. 2011; 16:949–959. [PubMed: 21079607]
43. Scott-Van Zeeland AA, Bloss CS, Tewhey R, Bansal V, Torkamani A, Libiger O, Duvvuri V,
Wineinger N, Galvez L, Darst BF, Smith EN, Carson A, Pham P, Phillips T, Villarasa N, Tisch R,
Zhang G, Levy S, Murray S, Chen W, Srinivasan S, Berenson G, Brandt H, Crawford S, Crow S,
Fichter MM, Halmi KA, Johnson C, Kaplan AS, La Via M, et al. Evidence for the role of EPHX2
gene variants in anorexia nervosa. Mol Psychiatry. 2013
44. Gendall K, Joyce P, Carter F, McIntosh V, Jordan J, Bulik C. The psychobiology and diagnostic
significance of amenorrhea in patients with anorexia nervosa. Fertil Steril. 2006; 85:1531–1535.
[PubMed: 16600234]
45. Pinheiro A, Thornton L, Plotonicov K, Tozzi T, Klump K, Berrettini W, Brandt H, Crawford S,
Crow S, Fichter M, Goldman D, Halmi K, Johnson C, Kaplan A, Keel P, LaVia M, Mitchell J,
Rotondo A, Strober M, Treasure J, Woodside D, Kaye W, Bulik C. Patterns of menstrual
disturbance in eating disorders. Int J Eat Disord. 2007; 40:424–434. [PubMed: 17497704]
46. Tozzi F, Thornton L, Klump K, Bulik C, Fichter M, Halmi K, Kaplan A, Strober M, Woodside D,
Crow S, Mitchell J, Rotondo A, Mauri M, Cassano C, Keel P, Plotnicov K, Pollice C, Lilenfeld L,
Berrettini W, Kaye W. Symptom fluctuation in eating disorders: correlates of diagnostic crossover.
Am J Psychiatry. 2005; 162:732–740. [PubMed: 15800146]
47. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the
next generation of genome-wide association studies. PLoS Genet. 2009; 5:e1000529. [PubMed:
19543373]
48. Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, Bonnen PE, de Bakker
PI, Deloukas P, Gabriel SB, Gwilliam R, Hunt S, Inouye M, Jia X, Palotie A, Parkin M, Whittaker
P, Chang K, Hawes A, Lewis LR, Ren Y, Wheeler D, Muzny DM, Barnes C, Darvishi K, Hurles
M, Korn JM, Kristiansson K, Lee C, McCarrol SA, et al. Integrating common and rare genetic
variation in diverse human populations. Nature. 2010; 467:52–58. [PubMed: 20811451]
49. Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nat Rev Genet.
2010; 11:499–511. [PubMed: 20517342]
50. Magi R, Morris AP. GWAMA: software for genome-wide association meta-analysis. BMC
Bioinformatics. 2010; 11:288. [PubMed: 20509871]
51. Morris JA, Randall JC, Maller JB, Barrett JC. Evoker: a visualization tool for genotype intensity
data. Bioinformatics. 2010; 26:1786–1787. [PubMed: 20507892]
Boraska et al. Page 18
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s52. Huckins L, Boraska V, Franklin C, Floyd J, Southam L, Nervosa GCfA, 3 WTCCC. Sullivan P,
Bulik C, Collier D, Tyler-Smith C, Zeggini E, Tachmazidou I. Using ancestry-informative markers
to identify fine structure across 15 populations of European origin. Eur J Hum Genet. in press.
53. Wang K, Zhang H, Bloss CS, Duvvuri V, Kaye W, Schork NJ, Berrettini W, Hakonarson H, Price
Foundation Collaborative Group. A genome-wide association study on common SNPs and rare
CNVs in anorexia nervosa. Mol Psychiatry. 2011; 16:949–959. [PubMed: 21079607]
54. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide
association analysis. Bioinformatics. 2007; 23:1294–1296. [PubMed: 17384015]
55. Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies. Nat
Genet. 2012; 44:821–824. [PubMed: 22706312]
56. Gauderman WJ. Candidate gene association analysis for a quantitative trait, using parent-offspring
trios. Genet Epidemiol. 2003; 25:327–338. [PubMed: 14639702]
57. R: A language and environment for statistical computing. 2008. http://www.R-project.org
58. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait
analysis. Am J Hum Genet. 2011; 88:76–82. [PubMed: 21167468]
59. Boraska V, Davis OS, Cherkas LF, Helder SG, Harris J, Krug I, Liao TP, Treasure J, Ntalla I,
Karhunen L, Keski-Rahkonen A, Christakopoulou D, Raevuori A, Shin SY, Dedoussis GV,
Kaprio J, Soranzo N, Spector TD, Collier DA, Zeggini E. Genome-wide association analysis of
eating disorder-related symptoms, behaviors, and personality traits. Am J Med Genet B
Neuropsychiatr Genet. 2012; 159B:803–811. [PubMed: 22911880]
60. Wade T, Gordon S, Medland, Bulik CM, Heath A, Montgomery GW, Martin NG. Genetic variants
associated with disordered eating. Int J Eat Disord. 2013; 46:594–608. [PubMed: 23568457]
61. Fall T, Ingelsson E. Genome-wide association studies of obesity and metabolic syndrome. Mol
Cell Endocrinol. 2012
62. Guo Y, Lanktree MB, Taylor KC, Hakonarson H, Lange LA, Keating BJ. Gene-centric meta-
analyses of 108 912 individuals confirm known body mass index loci and reveal three novel
signals. Hum Mol Genet. 2013; 22:184–201. [PubMed: 23001569]
63. Neale BM, Medland SE, Ripke S, Asherson P, Franke B, Lesch KP, Faraone SV, Nguyen TT,
Schafer H, Holmans P, Daly M, Steinhausen HC, Freitag C, Reif A, Renner TJ, Romanos M,
Romanos J, Walitza S, Warnke A, Meyer J, Palmason H, Buitelaar J, Vasquez AA, Lambregts-
Rommelse N, Gill M, Anney RJ, Langely K, O’Donovan M, Williams N, Owen M, et al. Meta-
analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J Am Acad
Child Adolesc Psychiatry. 2010; 49:884–897. [PubMed: 20732625]
64. Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N, Edenberg HJ, Nurnberger JI Jr.
Rietschel M, Blackwood D, Corvin A, Flickinger M, Guan W, Mattingsdal M, McQuillin A,
Kwan P, Wienker TF, Daly M, Dudbridge F, Holmans PA, Lin D, Burmeister M, Greenwood TA,
Hamshere ML, Muglia P, Smith EN, Zandi PP, Nievergelt CM, McKinney R, Shilling PD, et al.
Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility
locus near ODZ4. Nat Genet. 2011; 43:977–983. [PubMed: 21926972]
65. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011; 43:969–
976. [PubMed: 21926974]
66. A mega-analysis of genome-wide association studies for major depressive disorder. Mol
Psychiatry. 2013; 18:497–511. [PubMed: 22472876]
67. Watson HJ, Bulik CM. Update on the treatment of anorexia nervosa: review of clinical trials,
practice guidelines and emerging interventions. Psychol Med. 2012:1–24.
68. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J
Epidemiol. 2002; 155:478–484. [PubMed: 11867360]
69. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H,
Lindgren CM, Luan J, Magi R, Randall JC, Vedantam S, Winkler TW, Qi L, Workalemahu T,
Heid IM, Steinthorsdottir V, Stringham HM, Weedon MN, Wheeler E, Wood AR, Ferreira T,
Weyant RJ, Segre AV, Estrada K, Liang L, Nemesh J, Park JH, Gustafsson S, Kilpelainen TO, et
al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass
index. Nat Genet. 2010; 42:937–948. [PubMed: 20935630]
70. Hinney A, Hebebrand J. Three at one swoop! Obes Facts. 2009; 2:3–8. [PubMed: 20054198]
Boraska et al. Page 19
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s71. Bradfield JP, Taal HR, Timpson NJ, Scherag A, Lecoeur C, Warrington NM, Hypponen E, Holst
C, Valcarcel B, Thiering E, Salem RM, Schumacher FR, Cousminer DL, Sleiman PM, Zhao J,
Berkowitz RI, Vimaleswaran KS, Jarick I, Pennell CE, Evans DM, St Pourcain B, Berry DJ,
Mook-Kanamori DO, Hofman A, Rivadeneira F, Uitterlinden AG, van Duijn CM, van der Valk
RJ, de Jongste JC, Postma DS, et al. A genome-wide association meta-analysis identifies new
childhood obesity loci. Nat Genet. 2012; 44:526–531. [PubMed: 22484627]
72. Scherag A, Dina C, Hinney A, Vatin V, Scherag S, Vogel CI, Muller TD, Grallert H, Wichmann
HE, Balkau B, Heude B, Jarvelin MR, Hartikainen AL, Levy-Marchal C, Weill J, Delplanque J,
Korner A, Kiess W, Kovacs P, Rayner NW, Prokopenko I, McCarthy MI, Schafer H, Jarick I,
Boeing H, Fisher E, Reinehr T, Heinrich J, Rzehak P, Berdel D, et al. Two new loci for body-
weight regulation identified in a joint analysis of genome-wide association studies for early-onset
extreme obesity in French and German study groups. PLoS Genet. 2010; 6:e1000916. [PubMed:
20421936]
73. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum
Genet. 2012; 90:7–24. [PubMed: 22243964]
74. Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of psychiatric disorders: the emerging
picture and its implications. Nat Rev Genet. 2012; 13:537–551. [PubMed: 22777127]
75. Ripke S, O’Dushlaine C, Chambert K, Moran J, Kähler A, Akterin S, Bergen S, Collins A,
Crowley J, Fromer M, Kim Y, Lee S, Magnusson P, Sanchez N, Stahl E, Williams S, Wray N, Xia
K, Bettella F, Børglum A, Cormican P, Craddock N, de Leeuw C, Durmishi N, Gill M, Golimbet
V, Hamshere ML, Holmans P, Hougaard D, Kendler K, et al. Genome-wide association analysis
identifies 13 new risk loci for schizophrenia. Nat Genet. 2013; 45:1150–1159. [PubMed:
23974872]
Boraska et al. Page 20
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sFigure 1.
Analysis of RNAseq data for whole-brain tissue obtained from 12 different mouse strains for
32 mouse orthologues of the 34 human genes for which association to anorexia nervosa
(AN) was identified. The average FPKM (Fragments Per Kilobaseof exon per Million
fragments mapped) values for 32 genes across 12 mouse strains are shown.
Boraska et al. Page 21
Mol Psychiatry. Author manuscript; available in PMC 2013 December 11.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
Boraska et al. Page 22
Table 1
List of ethnicities and numbers of samples for main case control and anorexia nervosa (AN) subtype analyses
across discovery and replication datasets
Country
Cases
(% of
females)
AN
RESTRICTING
subtype cases
AN BINGE-
PURGE subtype
cases
Controls
(% of females)
Discovery dataset*
Canada 54 24 25 417 (46.52)
Czech Republic 72 40 29 331 (35.04)
Finland 131 39 29 404 (100)
France 293 137 135 619 (60.09)
Germany 475 147 55 1,205 (49.13)
Greece 70 10 5 79 (100)
Italy-North 203 103 99 841 (52.19)
Italy-South 75 31 26 52 (100)
Netherlands 348 115 90 593 (51.26)
Norway 82 24 15 602 (67.44)
Poland 175 68 107 564 (29.43)
Spain 186 45 44 185 (75.14)
Sweden 39 28 11 975 (72.10)
UK 213 97 97 5,163 (49.43)
USA 491 311 165 2,830 (41.31)
Total discovery 2,907 1,219 932 14,860 (51.73)
In silico replication
USA-Hakonarson 1,033 (97.67) 0 0 3,775 (45.85)
Estonia 31 (100) 0 0 106 (100)
De novo replication
Austria 48 (100) 0 0 183 (65.03)
Czech Republic 32 (71.88) 0 0 22 (100)
Finland 15 (100) 0 0 94 (8.51)
France 55 (100) 0 0 123 (100)
Germany 174 (99.43) 31 64 380 (66.84)
Greece 16 (100) 0 0 53 (100)
Italy-South 156 (96.79) 32 24 63 (100)
Netherlands 229 (100) 45 23 380 (27.11)
Poland 52 (98.08) 0 0 93 (100)
Spain 10 (100) 0 0 328 (41.46)
UK 155 (100) 28 55 199 (65.83)
USA** 671 (100) 349 272 2,830 (41.31)
Japan 458 (100) 213 240 421 (100)
Total replication 3,135 (98.72) 698 678 9,050 (50.08)
Total global meta-
analysis 5,551 1,606 1,445 21,080
*
All AN cases from discovery dataset were females.
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**
USA samples from discovery dataset were merged together with USA replication samples for replication analysis. The same USA control
dataset was used.
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